MedTrace Logo

A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

NCT00394563 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2009-10-12

No results posted yet for this study

Summary

The purpose of this study is to look at the effects of RN624 on moderate to severe knee pain due to osteoarthritis. This study will look at the safety and pain relieving effects of RN624 compared to placebo over a 4 month period.

Conditions

Interventions

DRUG

RN624 (PF-04383119)

10 mcg/kg

DRUG

RN624 (PF-04383119)

25 mcg/kg

DRUG

RN624 (PF-04383119)

50 mcg/kg

DRUG

RN624 (PF-04383119)

100 mcg/kg

DRUG

RN624 (PF-04383119)

200 mcg/kg

DRUG

placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00394563 on ClinicalTrials.gov